Misoprostol in Pregnancy: Clinical Use and Safety
Misoprostol is contraindicated in pregnant women who wish to continue their pregnancy, as it causes uterine contractions, bleeding, and abortion, and carries significant teratogenic risk when pregnancy continues after failed abortion attempts. 1
Approved Indications for Misoprostol Use in Pregnancy
Misoprostol has legitimate obstetric uses despite its contraindication for ulcer prevention during pregnancy:
1. Medication Abortion (14-27 Weeks Gestation)
For second-trimester medication abortion, use mifepristone 200 mg followed 36-48 hours later by misoprostol 400 mcg sublingually or buccally every 3 hours until expulsion. 2
Key dosing principles:
- Mifepristone-misoprostol combination: Mifepristone 200 mg orally, then misoprostol 400 mcg every 3 hours (sublingual/buccal preferred) 2
- Misoprostol-only regimen (if mifepristone unavailable): 400-600 mcg every 4-6 hours; higher doses (400-600 mcg) are more effective than 200 mcg 2
- Most patients complete abortion within 48 hours; up to 6 doses typically sufficient 2
- "Unlimited dosing" protocols show high effectiveness and safety 2
2. Early Pregnancy Termination (≤49 Days)
Use mifepristone 200 mg followed 24-48 hours later by misoprostol 800 mcg (vaginal or sublingual route). 3, 4
- The 800 mcg dose is superior to 400 mcg (94.2% vs 90.5% complete abortion) 3
- Concurrent administration is significantly less effective (68.8% vs 84.3% success) and should not be used 4
- Vaginal and sublingual routes have similar efficacy, but vaginal causes fewer side effects 3
3. Intrauterine Fetal Death (IUFD)
Dose misoprostol based on gestational age: 13-17 weeks use 200 mcg every 6 hours; 18-26 weeks use 100 mcg every 6 hours; ≥27 weeks use 25-50 mcg every 4 hours, all vaginally. 5
4. Labor Induction at Term (Off-Label)
For cervical ripening at term, oral misoprostol 25 mcg every 2 hours or 50 mcg every 4 hours appear comparably safe, though this remains off-label use. 6
Critical Safety Considerations
Absolute Contraindications:
High-Risk Scenarios Requiring Dose Reduction:
In women with prior cesarean section(s), use minimum effective doses and never exceed 100 mcg per dose. 7
- Risk of uterine rupture increases with:
- Misoprostol should not be used in third trimester with history of cesarean or major uterine surgery 1
Teratogenic Risk:
If pregnancy continues after failed misoprostol abortion attempt, there is 5.5% risk of major malformations, including Möbius sequence, hydrocephalus, limb reduction defects, and encephalocele. 8
- This risk appears higher (7.9%) after failed voluntary abortion attempts 8
- Teratogenic effects occur even with low doses 8
- Counsel patients that pregnancy must be terminated if misoprostol fails, or accept significant malformation risk
Maternal Complications:
- Uterine rupture: Requires surgical repair, possible hysterectomy; risk increases with uterine scar, advanced gestation, grand multiparity 1
- Retained placenta: Most common complication in second-trimester medication abortion 2
- Hemorrhage: Particularly with placenta previa; fetal asystole induction may reduce blood loss 9
- High fever (>40°C): Can occur with postpartum hemorrhage management, may include autonomic/CNS effects (tachycardia, disorientation, seizures) 1
Monitoring Requirements
- Uterine activity and fetal status must be monitored by trained obstetrical personnel in hospital setting when used for labor induction 1
- Clinical monitoring continues after delivery due to atony/retention risk 5
- Follow-up required to confirm complete abortion 3, 4
Common Pitfalls to Avoid
- Never use concurrent mifepristone-misoprostol administration - significantly less effective 4
- Never use 400 mcg misoprostol dose for early abortion - 800 mcg is required 3
- Never exceed 100 mcg per dose with uterine scar 7
- Never assume pregnancy is safe to continue after misoprostol exposure - teratogenic risk is substantial 8
- Never use in third trimester with prior cesarean - unacceptable rupture risk 1
Breastfeeding
Misoprostol is rapidly metabolized to active misoprostol acid and excreted in breast milk; exercise caution but no published reports of adverse effects in nursing infants 1